Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 696 results

Media Release / Nov 07, 2015

Up to 80% of ankylosing spondylitis patients treated with Cosentyx® show no spinal x-ray progression as shown in Novartis new two-year observational data
Media Release / Nov 07, 2015

Approximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data
Media Release / Oct 29, 2015

FDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease

- Utibron Neohaler (indacaterol/glycopyrrolate) demonstrated superior and sustained improvements in lung function compared to either of its single bronchodilator components as well as placebo, and…
Media Release / Oct 29, 2015

FDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease
Media Release / Oct 27, 2015

Novartis Clarification on Specialty Pharmacy Settlement in Principle Announcement

As part of Q3 Earnings, Novartis announced that it reached a settlement in principle in the suit related to the Company's interactions with specialty pharmacies. Some media coverage did not…
Media Release / Oct 27, 2015

Novartis Clarification on Specialty Pharmacy Settlement in Principle Announcement
Media Release / Sep 30, 2015

Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis

-- In the FUTURE 1 study, secukinumab met the primary endpoint showing statistically significant efficacy versus placebo in improving signs and symptoms of active psoriatic arthritis (PsA)-- All pre-…
Media Release / Sep 30, 2015

Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
Media Release / Sep 28, 2015

Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®

Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + MekinistTafinlar + Mekinist combination also demonstrated…
Media Release / Sep 27, 2015

Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®

‹ Previous page
1
…
45
46
47
48
49
50
51
…
70
› Next page